What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · IBB, NUVA

GSK is reportedly buying Nuvalent for $9B — trade the takeover premium

British drug giant GSK is reportedly in advanced talks to buy biotech company Nuvalent for over $9 billion. This is part of a massive wave of pharmaceutical companies acquiring smaller firms to get their hands on new, upcoming drugs.

Idea

When a large pharmaceutical company announces a multi-billion dollar takeover, the target company's stock usually jumps close to the offer price. Because GSK is paying a massive premium, Nuvalent shares will likely stay elevated or continue to creep up toward the final deal price. By betting on Nuvalent while betting against the broader biotech sector, you isolate the specific takeover premium while protecting yourself from a general stock market drop.

Key details

IBB NUVA1D#biotech#ma#acquisition

Community

Upvotes

Views

Copies

Cosigns

News sources

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT — CNBC

GSK is reportedly buying Nuvalent for $9B — trade the takeover premium

Idea

Key details

Community

News sources

Related ideas

Related